Mucormycosis coinfection in patients with proven aspergillosis

Hyeon Mu Jang1, Ji Yeun Kim1,2, Joon Seon Song3

  • 1Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, 05505 Seoul, Republic of Korea.

Medical Mycology
|March 21, 2025
PubMed

Insights

Coinfection with mucormycosis was found in 12% of patients with aspergillosis, particularly in rhino-paranasal cases. This study highlights the need for further research into the clinical impact of mold coinfections.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Molecular Diagnostics

Background:

  • Coinfection by molds, specifically mucormycosis alongside aspergillosis, is understudied.
  • Understanding coinfection patterns is crucial for accurate diagnosis and patient management.

Purpose of the Study:

  • To systematically investigate mucormycosis coinfection in patients with proven aspergillosis.
  • To determine the prevalence and clinical associations of mold coinfections.

Main Methods:

  • Retrospective review of adult patients with proven aspergillosis and available FFPE tissue.
  • Fungal culture and Aspergillus- and Mucorales-specific PCR on FFPE tissues.
  • Confirmation of Mucorales PCR via positive 18S and 28S targets.

Main Results:

  • Overall, 12% (6/49) of patients with aspergillosis had evidence of mucormycosis coinfection.
  • Mucormycosis coinfection was significantly associated with rhino-paranasal sinus involvement (33% vs. 2%, P=0.03).
  • No significant difference in in-hospital mortality was observed between coinfected and non-coinfected groups.

Conclusions:

  • Approximately 10% of patients with aspergillosis exhibit evidence of mucormycosis coinfection.
  • Rhino-paranasal aspergillosis cases show a higher likelihood of mucormycosis coinfection.
  • Further research is warranted to elucidate the clinical significance of molecularly detected mucormycosis coinfection.